Loading patent…
AssigneeMacroGenics, Inc.
InventorsLeslie S. Johnson, Ling Huang, Robyn Gerena
Estimating the term…
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
1-22. (canceled)
An isolated antibody, or an antigen-binding fragment thereof, that binds human FcγRIIB, said antibody or fragment thereof comprising three light chain complementarity determining regions (CDR) and three heavy chain CDRs from 8B5.3.4 antibody produced by hybridoma cell line having ATCC accession number PTA-7610, or a derivative thereof having no more than one amino acid substitution in each of the three light chain CDRs and the three heavy chain CDRs.
A method of enhancing antibody-dependent cell mediated cytotoxicity (ADCC) activity of an anti-cancer antibody or antigen-binding fragment thereof, comprising administering to a patient in need thereof:
Dependencies are inferred from the claim text.